Pius-Hospital Oldenburg — Clinical Trial Site

53 Registered trials

22 Currently recruiting

Organisation

Pius-Hospital Oldenburg

Location

Oldenburg, Germany

Identifier

ORG-100034299

Address

Georgstrasse 12, Innenstadt, 26121, Germany

Departments

-
2608: Internistische Onkologie
4503 :Klinik für Hämatologie und Onkologie
Abteilung für internistische Onkologie
Department of Hematology and Oncology
Haematologie und Internistische Onkologie
Haematologie und Onkologie
Haematology and Oncology
Hämatologie und Onkologie
Hematology and Oncology
Innere Medizin - Onkologie
Internistische Onkologie
Klinik f. Hämatolgie und Onkologie
Klinik fuer Haematologie und Onkologie
Klinik für Häematologie und Onkologie
Klinik für Hämatologie und Onkologie
Klinik für Hämatologie und Onkologie Universitätsklinik für Innere Medizin — Onkologie
Klinik für Hämatologie und Onkologie, Cancer Center Oldenburg
Klinik für Hämatologie und Onkologie, Universitätsklinik für Innere Medizin Onkologie
Klinikzentrum für Strahlentherapie, Hämatologie und Onkologie
Medical Oncology
Oncology
Pius Hospital Oldenburg
Universitätsklinik für Augenheilkunde
Universitätsklinik für Innere Medizin - Onkologie Klinik für Hämatologie und Onkologie
Universitätsklinik für Innere Medizin – Onkologie, Klinik für Hämatologie und Onkologie
Universitätsklinik für Onkologie
Universitätsklinik für Strahlentherapie, Hämatologie und Onkologie

Clinical trials at this site (53)

Search interface

BMS-986489 (BMS-986012 + Nivolumab Fixed Dose Combination) with Chemotherapy vs Atezolizumab with Chemotherapy as First-line Therapy in Part… Ended

2024-515740-23-00 Extensive-Stage Small Cell Lung Cancer (ES-SCLC) 5 2025-03-25
ANTELOPE – Atezolizumab/Carboplatin/nab-Paclitaxel vs. Pembrolizumab/Platinum/Pemetrexed in metastatic TTF-1 negative lung adenocarcinoma Ended

2023-505054-17-00 metastatic TTF-1 negative lung adenocarcinoma 6 2023-09-15
A Global Study to Assess the Effects of Durvalumab with Oleclumab or Durvalumab with Monalizumab Following Concurrent Chemoradiation in Pati… Ended

2023-503999-24-00 Patients With Locally Advanced (Stage III), Unresectabl 5 2022-06-01
A Phase II, single-arm trial of Atezolizumab/Platinum/Etoposide for the treatment of advanced large-cell neuroendocrine cancer of the lung (… Ended

2024-515902-15-00 Male and female adult patients with locally advanced or 4 2022-01-18
A study to investigate the efficacy and safety of trastuzumab deruxtecan as the first treatment option for locally advanced/metastatic Non-S… Ended

2023-503674-20-00 Unresectable, locally advanced, or metastatic Non-Small 5 2021-12-17
Additional chemotherapy for EGFRm patients with the continued presence of plasma ctDNA EGFRm at week 3 after start of osimertinib 1st-line t… Ended

2024-517965-18-00 Advanced NSCLC with common EGFR-Mutation 4 2021-11-11
Low-dose AtropIne for Myopia control in children Ended

2024-513091-17-00 Progressive myopia 5 2021-09-29
A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lun… Ended

2023-507494-18-00 Non-small cell lung cancer with ROS proto-oncogene 1, r 5 2021-09-24
Optimizing MATRix, a combination of Methotrexate, Ara-C, Thiotepa and Rituximab given as an induction therapy, de-escalated in duration and … Ended

2024-514473-21-00 Primary diffuse large B-cell lymphoma (DLBCL) of the ce 5 2021-06-21
A Study of Osimertinib with or without Chemotherapy versus Chemotherapy alone as neoadjuvant therapy for Patients with Epidermal Growth Fact… Ended

2022-502606-33-00 Patients with histologically or cytologically documente 5 2021-02-26
A Randomized Prospective Trial of Adjuvant Chemotherapy in Patients with Completely Resected Stage I or IIA Non-Squamous Non-Small Cell Lung… Ended

2024-511185-37-00 Completely resected stage I or IIA non-squamous non-sma 6 2020-11-03
A Clinical Study to Evaluate the Safety and Pharmacokinetics of JNJ- 73841937 (Lazertinib), a Third Generation EGFR-TKI, as Monotherapy or i… Ended

2023-506577-35-00 Advanced Non-Small Cell Lung Cancer 3 2020-09-08
Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200) Ended

2023-508214-42-00 Previously treated locally advanced and unresectable or 5 2020-05-25
ABP - Advancing Brigatinib Properties in anaplastic lymphoma kinase positive nonsmall cell lung cancer (ALK+ NSCLC) patients by deep phenoty… Ended

2024-513947-94-00 locally advanced (stage III) and not suitable for curat 4 2020-03-30
Short course radiotherapy versus chemoradiotherapy, followed by consolidation chemotherapy, and selective organ preservation for MRI-defined… Ended

2024-511577-29-01 intermediate and high-risk rectal cancer 5 2020-03-13
Prospective Phase-II Trial of induction chemotherapy and chemoradiotherapy plus/minus the PD-L1 antibody durvalumab followed by surgery or d… Ended

2024-513039-26-00 non-small cell lung cancer stages IIIA (N2) and selecte 4 2019-11-25
Copanlisib and Rituximab in Marginal Zone Lymphoma Patients - A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY (COUP-1) Ended

2022-500674-34-00 Marginal Zone Lymphoma 4 2019-11-04
Randomized Phase III Study of Standard Intensive Chemotherapy versus Intensive Chemotherapy with CPX-351 in Adult Patients with Newly Diagno… Ended

2023-503670-21-00 Patients with newly diagnosed AML and intermediate- or 5 2019-08-28
Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Foll… Ended

2023-509602-29-00 Patients with Limited Stage Small-Cell Lung Cancer (LS- 5 2019-02-11
Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lun… Ended

2023-505981-26-00 Non−Small Cell Lung Cancer 5 2015-11-20
Study of efficacy and safety of JDQ443 single-agent as first-line treatment for patients with locally advanced or metastatic KRAS G12C- muta… Halted

2024-511708-18-00 Locally advanced or metastatic KRAS G12C-mutated non-sm 4 2022-12-06
A Study to Assess Disease Activity of Intravenously (IV) Infused Telisotuzumab Vedotin in Adult Participants with Advanced/Metastatic Non-Sq… Ended

2022-500608-23-00 Previously Untreated MET Amplified Locally Advanced/Met 4 2023-04-06
TSRO-Ph2, Dostarlimab +CT vs Pembro +CT, 1L H2H efficacy comparison in Metastatic NSCLC pts. PERLA Ended

2023-505894-33-00 Lung Cancer, Non-Small Cell 4 2020-11-25
A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) (AcceleRET-Lung) Ended

2023-505035-12-00 RET fusion−positive, metastatic Non-Small Cell Lung Can 5 2020-06-12